about
Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literatureAcute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-upVirological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.Epidemiology and diagnosis of tuberculous lymphadenitis in a tuberculosis low-burden country.Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patientsUltrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patientsTropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain.Double-boosted protease inhibitor antiretroviral regimens: what role?From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.Management of tuberculosis in HIV-infected patients.Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men.Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment.The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM.Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC.Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain.Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis.Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease.Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome.LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.[Darunavir as first-line therapy. The TITAN study].Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.Peak bone mass in young HIV-infected patients compared with healthy controls.Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
P50
Q28082149-B6D075A2-7519-494B-99F2-381A55F7BD95Q28302032-6ED68AEB-AC37-46B0-9A7C-5392C4EC8B79Q34906495-92AE4190-9355-4E76-A0F2-836DC636CC07Q36153412-3D2043A9-B9B4-4400-8FAF-84D726B39EBDQ36158135-15081E99-894E-405B-9812-A84CAF5194BFQ37107899-7BE24E77-79DC-4CEF-93E1-4C113BD14A17Q37119579-B59F3AAD-90AC-4AB6-8F19-2B8EBDED68A8Q37313399-07D32866-26F9-43F2-AFB4-06E92C3C70A5Q37828539-57475158-71D3-40FD-8D8C-0AC1BE1A5AF9Q38069084-8A5E4C43-DEFC-4BAA-893A-F4846196BAA3Q38512796-7F0B432B-ACCA-404B-894A-3E36F83CB31FQ39477718-7B8893C1-A3D9-4D67-9752-D87CE520F8E8Q40188071-98F67D23-91C5-49BE-A30E-5BA3CCE15BA0Q40836654-27EE7E92-0FBF-46F1-8064-1CB869D4D98FQ41337231-6EE42660-04E4-4B1A-A414-85A7782DDB8FQ41350233-5429A9C2-11DF-48CE-A549-CD36A90B9415Q41363639-5C7D5375-E4F9-4478-8CA6-EC3931C403BEQ41590742-DAF71D06-46C6-4CA3-A33A-18A139F0FA1BQ41605464-DE001800-E09E-4290-9D35-825AD8B5C822Q41663854-65790279-9DE9-4F36-9C80-986484AA90D6Q41733883-EDF3DBFA-CBAD-49D5-8651-7AAF3DD00F19Q42200753-37695AAF-A268-4D1E-8452-7A4074192476Q42233296-DDA8E4DF-727E-45CF-BC4C-A7D6EB373251Q42243725-FEFFFA27-06EA-48B7-A35F-62EBFBA6E759Q42279735-007E4942-69CE-4F4D-A292-B795E5E33950Q42787154-F19B8D1B-943A-413F-B546-D44C7B723BB1Q42936157-33AFA7AF-960B-4F92-9D3A-71E5EDACC8C5Q42986040-262FAB2F-74D4-4CF4-BEFA-B785F125A471Q43047302-E17B6728-25A0-4AE2-BE3F-6CA6413F254FQ43237663-5A590E0D-D061-4BBF-B79B-FD3EADB419A2Q43298626-034D8C26-AADA-47B5-8709-73CFF8ED499EQ43452495-6A7E012E-AC26-488A-964C-0A80A1CEE846Q43491359-98892ECD-7568-47F4-BB0B-5309923D03C7Q43497530-72416525-7EA4-43A6-BA41-E5B219E181DAQ43572922-89D879ED-89B9-4701-84EF-DDC9E5959DC3Q43770019-936A761D-AE3A-4677-9086-D939584997A6Q43926822-DB5000D4-B9D9-4060-A3AB-6B36F9D5B48EQ43940324-67AD975D-0276-47F8-9901-CDC0B1514643Q45075780-F34AA5CE-FC65-408F-A00D-CC3B99F577C5Q46034285-55702D4A-B5FB-4982-B86C-BE7BD643087E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Adrian Curran
@ast
Adrian Curran
@en
Adrian Curran
@es
Adrian Curran
@nl
type
label
Adrian Curran
@ast
Adrian Curran
@en
Adrian Curran
@es
Adrian Curran
@nl
prefLabel
Adrian Curran
@ast
Adrian Curran
@en
Adrian Curran
@es
Adrian Curran
@nl
P106
P21
P31
P496
0000-0002-1263-0814